Ali Rizvi to Aged
This is a "connection" page, showing publications Ali Rizvi has written about Aged.
Connection Strength
0.269
-
Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. Expert Opin Biol Ther. 2015; 15(10):1391-7.
Score: 0.042
-
The "calcium supplement syndrome": modern-day reemergence of a bygone disorder. J S C Med Assoc. 2013 Sep; 109(3):88-91.
Score: 0.037
-
Impact of comprehensive diabetes specialty care in the management of older adults with stage 3 or 4 nephropathy. South Med J. 2009 Sep; 102(9):985.
Score: 0.028
-
Management of diabetes in older adults. Am J Med Sci. 2007 Jan; 333(1):35-47.
Score: 0.023
-
Parasellar meningioma resembling a pituitary tumor. Endocr Pract. 2007 Jan-Feb; 13(1):86-8.
Score: 0.023
-
Levofloxacin-induced hypoglycemia in a nondiabetic patient. Am J Med Sci. 2006 Jun; 331(6):334-5.
Score: 0.022
-
Primary ovarian lymphoma manifesting with severe hypercalcemia. Endocr Pract. 2003 Sep-Oct; 9(5):389-93.
Score: 0.018
-
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetol. 2016 Dec 03; 15(1):162.
Score: 0.011
-
Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study. J Clin Endocrinol Metab. 2015 Feb; 100(2):603-6.
Score: 0.010
-
Impact of clinical and therapeutic factors on incident cardiovascular and cerebrovascular events in a population-based cohort of HIV-infected and non-HIV-infected adults. Clin Cardiol. 2014 Sep; 37(9):517-22.
Score: 0.010
-
Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol. 2014 Feb 22; 13:49.
Score: 0.009
-
Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial. Am Heart J. 2013 Dec; 166(6):1035-42.
Score: 0.009
-
Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2013 Sep; 6(9):914-22.
Score: 0.009
-
Association of clinical and therapeutic factors with incident dyslipidemia in a cohort of human immunodeficiency virus-infected and non-infected adults: 1994-2011. Metab Syndr Relat Disord. 2013 Dec; 11(6):417-26.
Score: 0.009
-
Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials. EuroIntervention. 2012 May 15; 8(1):87-93.
Score: 0.008